Keros Therapeutics Stock Investor Sentiment
| KROS Stock | USD 10.94 0.03 0.27% |
Slightly above 55% of Keros Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Keros Therapeutics suggests that many traders are impartial. Keros Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Keros Therapeutics' earnings reports, geopolitical events, and overall market trends.
Comfort Level 45
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Keros Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Keros Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentWaiting |
Keros Historical Sentiment
Although Keros Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Keros, such as negative comments on social media and news outlets, may cause fear in the market and push Keros Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Keros.
Keros |
Keros Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Keros Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Keros Therapeutics Historical Investor Sentiment
Investor biases related to Keros Therapeutics' public news can be used to forecast risks associated with an investment in Keros. The trend in average sentiment can be used to explain how an investor holding Keros can time the market purely based on public headlines and social activities around Keros Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Keros Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Keros Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Keros Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Keros Therapeutics.
Far too much social signal, news, headlines, and media speculation about Keros Therapeutics that are available to investors today. That information is available publicly through Keros media outlets and privately through word of mouth or via Keros internal channels. However, regardless of the origin, that massive amount of Keros data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Keros Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Keros Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Keros Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Keros Therapeutics alpha.
Keros Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial | 12/12/2024 |
2 | Piper Sandler Lowers Keros Therapeutics Price Target to 15.00 | 01/17/2025 |
3 | Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept | 01/21/2025 |
4 | Keros Therapeutics Stock Plunges 81 percent in 3 Months Heres Why - Yahoo Finance | 01/23/2025 |
5 | Keros Therapeutics Cut to Neutral at Cantor Fitzgerald | 01/24/2025 |
6 | Bronstein, Gewirtz Grossman, LLC Encourages Keros Therapeutics, Inc. Stockholders to Inquire about Securities Investigation - Markets Insider | 01/27/2025 |
7 | Keros Therapeutics CEO to Speak at Biotech Conference - TipRanks | 01/30/2025 |
8 | Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compounds Potential as a Therapeutic... | 02/06/2025 |
9 | Institutional owners may consider drastic measures as Keros Therapeutics, Inc.s recent US55m drop adds to long-term losses | 02/14/2025 |
10 | Acquisition by Rovaldi Christopher of 60000 shares of Keros Therapeutics subject to Rule 16b-3 | 02/18/2025 |
11 | Keros Therapeutics Inc Reports Q4 2024 EPS of -1. ... | 02/26/2025 |
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.